Peptidream Inc. (JP:4587)
:4587
Top Page
Peptidream
(4587)
Select Model
Select Model
Rating:46Neutral
Price Target:
¥1,174.00
▼(-29.66% Downside)
Action:ReiteratedDate:03/20/26
The score is held down primarily by weak recent financial performance (2025 loss and cash burn) and bearish technicals (price below all key moving averages with negative MACD). Earnings call details provide a partial offset via strong pipeline/clinical progress and a solid stated cash position, but near-term results remain sensitive to uncertain deal timing and rising cost plans; valuation is difficult to support given negative earnings and no provided dividend yield.
Positive Factors
Proprietary PDPS platform & scientific edge
PeptiDream's proprietary peptide discovery platform and recent scientific demonstrations (extrahepatic delivery, in vivo proof-of-concept immune engagers) create durable technical differentiation. This increases partner interest, supports recurring collaborations and strengthens long-term deal flow and platform monetization.
Negative Factors
2025 profit swing & cash-flow deterioration
The 2025 reversal from prior profitability to sizeable operating and free cash flow losses is a durable concern: sustained cash burn reduces margin for execution risk, limits discretionary investment, and raises reliance on milestone/upfront receipts or asset monetization to restore long-term financial stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary PDPS platform & scientific edge
PeptiDream's proprietary peptide discovery platform and recent scientific demonstrations (extrahepatic delivery, in vivo proof-of-concept immune engagers) create durable technical differentiation. This increases partner interest, supports recurring collaborations and strengthens long-term deal flow and platform monetization.
Read all positive factors
Peptidream (4587) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥157.22B
Dividend YieldN/A
Average Volume (3M)1.01M
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue Growth-62.47%
EPS Growth-134.06%
CountryJP
Employees621
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.11
Shares Outstanding130,010,400
10 Day Avg. Volume808,920
30 Day Avg. Volume1,013,253
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)4.16
Price to Sales (P/S)11.56
P/FCF Ratio-14.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,562.50Price Target Upside53.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)56.87
Revenue Forecast (FY)¥45.09B
Peptidream Business Overview & Revenue Model
Company Description
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform Sys...
How the Company Makes Money
PeptiDream primarily generates revenue through partnering and licensing activities built around its peptide discovery platform. Key revenue streams typically include: (1) upfront payments received when entering into collaboration or license agreem...
Peptidream Earnings Call Summary
Earnings Call Date:Feb 16, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call presented substantial operational and pipeline progress — notably strong clinical momentum (6 programs entering clinic in 2025, 13 total clinical programs), late-stage radiopharmaceutical programs with NDA timelines, IND acceptances and a healthy cash balance (JPY 28.6 billion). At the same time, key revenue drivers were delayed (notably the myostatin out‑licensing), R&D and headcount-driven costs are increasing (R&D +28% year-over-year; headcount +6.4%), and several high-value deals remain timing-uncertain. Overall, the company appears to be transitioning from a discovery-focused model to a discovery-and-development company with meaningful upside from pipeline advances, but near-term financial performance depends on timing of large upfront deals and execution of planned manufacturing expansions.Positive Updates
Strong Clinical Momentum — 2025
Six programs entered clinical development in FY2025, bringing the total to 13 clinical programs (an addition of 6 programs in the year). In total, 13 programs staged advanced across the portfolio during 2025.
Negative Updates
Missed/Delayed Out‑licensing of Oral Myostatin Program
The anticipated out‑licensing of the oral myostatin inhibitor did not conclude in FY2025, causing a material revenue shortfall versus prior forecasts. Management cited timing/partner fit and a desire to maximize asset value as reasons for delay.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Clinical Momentum — 2025
Six programs entered clinical development in FY2025, bringing the total to 13 clinical programs (an addition of 6 programs in the year). In total, 13 programs staged advanced across the portfolio during 2025.
Read all positive updates
Company Guidance
PeptiDream's FY2026 guidance calls for consolidated revenue of JPY 32.0 billion plus additional outsourcing/upfront payments (management referenced a potential upfront of ~JPY 14.0 billion), expects 6–12 programs to enter clinical development in 2026 and to close the year with 19–25 clinical programs (up from 13 at end‑2025 after six clinic entries in 2025), budgets R&D to increase to JPY 6.4 billion (from JPY 5.0 billion in FY2025), and notes cash of JPY 28.6 billion at end‑2025; the group’s headcount rose to ~810 (from 761), total 2025 costs (COGS+SG&A) were about JPY 23.5 billion, the company remains net‑cash positive with an improving equity ratio and no planned equity financing, and it is progressing capital projects (Tonomachi HQ construction now targeted for early 2027; Kazusa manufacturing to start late‑2026 and become operational in 2028).Peptidream Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
68
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 18.52B | 46.68B | 28.71B | 26.85B | 9.42B |
| Gross Profit | 7.52B | 34.16B | 16.86B | 17.81B | 6.96B |
| EBITDA | -2.85B | 23.64B | 9.61B | 11.32B | 4.68B |
| Net Income | -3.75B | 15.01B | 3.04B | 7.55B | 2.57B |
Balance Sheet | |||||
| Total Assets | 77.03B | 93.62B | 69.46B | 64.94B | 27.25B |
| Cash, Cash Equivalents and Short-Term Investments | 28.68B | 48.12B | 19.51B | 5.25B | 11.75B |
| Total Debt | 17.04B | 20.03B | 22.80B | 21.40B | 0.00 |
| Total Liabilities | 25.50B | 36.85B | 29.11B | 32.90B | 1.90B |
| Stockholders Equity | 51.53B | 56.76B | 40.35B | 32.04B | 25.35B |
Cash Flow | |||||
| Free Cash Flow | -14.92B | 21.77B | 11.17B | -4.02B | 5.47B |
| Operating Cash Flow | -13.28B | 23.84B | 12.38B | -295.73M | 6.65B |
| Investing Cash Flow | -2.05B | 8.37B | 1.30B | -27.38B | -2.28B |
| Financing Cash Flow | -4.06B | -2.99B | 302.19M | 21.00B | 66.07M |
Peptidream Technical Analysis
Negative
1669.00
Price Trends
1377.52
Negative
1523.20
Negative
1566.70
Negative
Market Momentum
-43.92
Negative
41.31
Neutral
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4587, the sentiment is Negative. The current price of 1669 is above the 20-day moving average (MA) of 1238.33, above the 50-day MA of 1377.52, and above the 200-day MA of 1566.70, indicating a bearish trend. The MACD of -43.92 indicates Negative momentum. The RSI at 41.31 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4587.
Peptidream Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ¥177.12B | -28.68 | -10.40% | ― | 13.78% | -110.02% | |
54 Neutral | ¥20.08B | 87.60 | ― | ― | 9.87% | -24.41% | |
52 Neutral | ¥137.39B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥92.40B | -5.96 | -19.31% | ― | -1.96% | -64.18% | |
47 Neutral | ¥22.99B | -4.22 | -184.71% | ― | 56.75% | -97.56% | |
46 Neutral | ¥157.22B | -57.13 | -10.16% | ― | -62.47% | -134.06% |
* Healthcare Sector Average
JP:4587
Peptidream
1,211.00
-679.50
-35.94%
JP:4563
AnGes
58.00
-6.00
-9.38%
JP:2160
GNI Group
3,180.00
1,364.00
75.11%
JP:4565
Sosei Group
1,021.00
281.00
37.97%
JP:4579
RaQualia Pharma Inc.
821.00
487.00
145.81%
JP:4974
Takara Bio Inc.
1,141.00
360.00
46.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.